Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies
AssigneeImmunomedics, Inc.
InventorsHans J. Hansen, Gary L. Griffiths, Shui-on Leung, William J. McBride, Zhengxing Qu
Life of this patent
Estimating the term…
Loading patent…
AssigneeImmunomedics, Inc.
InventorsHans J. Hansen, Gary L. Griffiths, Shui-on Leung, William J. McBride, Zhengxing Qu
Estimating the term…
The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them.
An isolated nucleic acid encoding a 679 antibody light chain variable region amino acid sequence, wherein said 679 antibody light chain variable region amino acid sequence comprises the complementarity determining region (CDR) sequences CDR1 (KSSQSLFNSRTRKNYLG, residues 24-40 of SEQ ID NO:2), CDR2 (WASTRES, residues 56-62 of SEQ ID NO:2) and CDR3 (TQVYYLCT, residues 95-102 of SEQ ID NO:2).
An isolated nucleic acid encoding a 679 antibody heavy chain variable region amino acid sequence, wherein said 679 antibody heavy chain variable region amino acid sequence comprises the CDR sequences CDR1 (IYTMS, residues 30-34 of SEQ ID NO:4), CDR2 (TLSGDGDDIYYPDSVKG, residues 49-65 of SEQ ID NO:4) and CDR3 (VRLGDWDFDV, residues 98-107 of SEQ ID NO:4).
An isolated nucleic acid encoding 679 antibody light and heavy chain variable region amino acid sequences, wherein said 679 antibody light chain variable region amino acid sequence comprises the CDR sequences CDR1 (KSSQSLFNSRTRKNYLG, residues 24-40 of SEQ ID NO:2), CDR2 (WASTRES, residues 56-62 of SEQ ID NO:2) and CDR3 (TQVYYLCT, residues 95-102 of SEQ ID NO:2) and said 679 antibody heavy chain variable region amino acid sequence comprises the CDR sequences CDR1 (IYTMS, residues 30-34 of SEQ ID NO:4), CDR2 (TLSGDGDDIYYPDSVKG, residues 49-65 of SEQ ID NO:4) and CDR3 (VRLGDWDFDV, residues 98-107 of SEQ ID NO:4).
Dependencies are inferred from the claim text.